Ofev 150 mg soft capsules
Sponsors
Assistance Publique Hopitaux De Paris, Hospices Civils De Lyon, Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
Conditions
Adult patients aged 18 and over with unicentric hyalino-vascular Castleman's diseaseHereditary haemorrhagic telangiectasiaidiopathic pulmonary fibrosissystemic sclerosis with interstitial lung disease (ILD) in the course of the disease
Phase 2
NUCastle - Nintedanib treatment in Unicentric Castleman disease
Not yet recruitingCTIS2023-510253-42-00
Target: 13Updated: 2025-02-05
Phase II randomized study on efficacy of nintedanib for treatment of epistaxis in hereditary haemorrhagic telangiectasia (HHT) patients - EPISTOP
RecruitingCTIS2024-518886-89-00
Start: 2025-06-16Target: 28Updated: 2025-11-03
Phase 3
Pragmatic management of progressive disease in idiopathic pulmonary fibrosis:
a randomized trial. PROGRESSION-IPF
CompletedCTIS2024-511427-34-00
Start: 2020-02-20End: 2026-01-09Target: 378Updated: 2025-01-08
A multicentre clinical trial evaluating the safety and efficacy of the combination of nintedanib and tocilizumab compared to standard treatment in patients with systemic sclerosis and interstitial lung disease. Analysis with theranostic approach and assessment of cytokine activity, markers of inflammation and pulmonary fibrosis using computed tomography, positron emission tomography, and metabolome and transcriptome studies in selected patients. NINTOC-TU study
RecruitingCTIS2024-517005-85-00
Start: 2025-07-01Target: 86Updated: 2024-10-16